Fmr LLC Raises Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Fmr LLC grew its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 2.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 8,363,530 shares of the company’s stock after acquiring an additional 170,810 shares during the quarter. Fmr LLC owned about 2.98% of Recursion Pharmaceuticals worth $55,116,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Axxcess Wealth Management LLC grew its position in Recursion Pharmaceuticals by 4.3% in the third quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock worth $289,000 after acquiring an additional 1,795 shares in the last quarter. Green Alpha Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 2.9% in the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock worth $427,000 after purchasing an additional 1,800 shares during the period. Interchange Capital Partners LLC increased its position in shares of Recursion Pharmaceuticals by 7.3% during the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after purchasing an additional 2,349 shares during the last quarter. Amalgamated Bank increased its position in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after purchasing an additional 2,459 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Recursion Pharmaceuticals by 13.5% during the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after buying an additional 2,598 shares during the period. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Performance

RXRX stock opened at $8.01 on Friday. Recursion Pharmaceuticals, Inc. has a twelve month low of $5.60 and a twelve month high of $15.74. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -5.24 and a beta of 0.85. The business’s fifty day simple moving average is $6.61 and its two-hundred day simple moving average is $7.34. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $26.08 million during the quarter, compared to analysts’ expectations of $12.62 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company’s quarterly revenue was up 147.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.43) EPS. Analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, November 20th. Leerink Partners dropped their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Finally, Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.25.

Insider Activity

In other news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $6.84, for a total transaction of $78,297.48. Following the transaction, the director now owns 7,109,875 shares of the company’s stock, valued at approximately $48,631,545. This represents a 0.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $7.00, for a total value of $42,000.00. Following the transaction, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,647,966. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 134,235 shares of company stock valued at $895,538. Corporate insiders own 15.75% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.